Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | APC inact mut |
Therapy | Erlotinib + Ibuprofen |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | colorectal cancer | sensitive | Erlotinib + Ibuprofen | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047). | 17909047 |
PubMed Id | Reference Title | Details |
---|---|---|
(17909047) | Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. | Full reference... |